Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
This study has been completed.
Study NCT01106131   Information provided by Chong Kun Dang Pharmaceutical

First Received on April 16, 2010.   Last Updated on February 13, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
CKD-501 0.5mg
Pioglitazone 15mg
Additional drug interventions recognized in this trial
Metformin
Pioglitazone
More general drug interventions related to this trial
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Chong Kun Dang Pharmaceutical


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services